- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05524155
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
August 31, 2022 updated by: Tongguo Si, Tianjin Medical University Cancer Institute and Hospital
Safety and Efficacy of Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Who Failed Second-line Therapy
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tongguo Si
- Phone Number: 18526812877
- Email: 18526812877@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign written informed consent before performing any trial related procedures
- ≥ 18 years old
- Histologically or cytologically proven unresectable metastatic colorectal cancer with liver metastases (AJCC 8th IV)
- Intolerance to second-line therapy, or disease progression during or after second-line therapy (RECIST V1.1)
- At least one radiographically measurable lesion, according to the RECIST V1.1 criteria
Patients with asymptomatic brain metastases or stable symptoms after local treatment were allowed to enroll if they met the following criteria:
- Measurable lesions outside the central nervous system
- No central nervous system symptoms, or symptoms not worsened for at least 2 weeks
- No glucocorticoid therapy was required or glucocorticoid therapy was discontinued within 7 days before the first study drug administration
- Palliative radiation therapy (including craniocerebral radiation for symptomatic brain metastases) was permitted, provided that the radiation had ended at least 1 week before enrollment and that the radiotherapy-related toxicity had recovered to grade 1 or less (CTCAE 5.0, except alopecia).
- ECOG PS scores 0-1
- The expected survival time was >3 months
Sufficient organ functions, the subjects need to meet the following laboratory indicators:
- ANC ≥1.5×10^9/L without the use of granulocyte colony-stimulating factor in the last 14 days
- Platelets ≥90×10^9/ without blood transfusion in the past 14 days
- Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days
- Total bilirubin ≤1.5× upper limit of normal (ULN); Or total bilirubin >ULN but direct bilirubin ≤ ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in ≤2.5×ULN (ALT or AST ≤5×ULN allowed in patients with liver metastases)
- Serum creatinine ≤ 1.5 × ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) ≥ 60 ml/min
- Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN
- Normal thyroid function, defined as thyroid stimulating hormone (TSH) within normal limits. If the baseline TSH was outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range could also be enrolled
- The myocardial zymogram is within the normal range (if the investigator comprehensively determines that the simple laboratory abnormality is not of clinical significance, it is also allowed to be enrolled)
- Pregnancy test negative and use birth control
Exclusion Criteria:
- Previous treatment with regorafenib
- Previous treatment with anti-PD-L1, anti-PD-L2 drugs, or other drugs that stimulates or synergistically inhibits T-cell receptors (e.g., CTLA-4, OX-40, CD137)
- Symptomatic or high risk of obstruction, bleeding, perforation, pneumonia (including noncommunicable pneumonia with previous hormonal therapy and pneumonia in patients receiving treatment)
- Malignancy other than colorectal cancer diagnosed within 5 years before the first dose (excluding radical basal cell carcinoma of the skin, squamous carcinoma of the skin, and/or carcinoma in situ after radical resection)
- currently participating in an interventional clinical study treatment, or has received another study drug or used a study device within 4 weeks prior to the first dose
- Systemic systemic therapy with proprietary Chinese medicine or immunomodulatory agents (including thymosin, interferon, and interleukin, except for local use to control pleural effusion) with anti-tumor indications was received within 2 weeks before the first dose
- Active autoimmune disease requiring systemic therapy occurred within 2 years before the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy
- Receiving systemic glucocorticoid therapy (excluding intranasal, inhaled, or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first dose; Physiological doses of glucocorticoids (≤10 mg/day or equivalent prednisone) are permitted
- Blood transfusion within 7 days before the first dose
- Clinically uncontrollable pleural effusion/abdominal effusion
- Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation
- Known allergy to the active ingredient or excipient of the study drug
- Not fully recovered from toxicity and/or complications caused by any intervention (≤ grade 1 or baseline, excluding fatigue or alopecia) before starting treatment
- HIV 1/2 antibody positive
Untreated active hepatitis B, subjects who met the following criteria could also be enrolled:
- HBV viral load <1000 copies/ml (200 IU/ml) before the first dose, subjects should receive anti-HBV therapy to avoid virus reactivation throughout the study
- Subjects with anti-HBC (+), HBsAg (-), anti-HBs (-), and HBV viral load (-) did not require prophylactic anti-HBV therapy, but did require close monitoring for viral reactivation
- Active HCV-infected
- Received live vaccine within 30 days prior to the first dose,Inactivated virus vaccines for injectable use against seasonal influenza are permitted up to 30 days before the first dose,live attenuated influenza vaccines administered intranasally not allowed
- Pregnant or lactating woman
- With any severe or uncontrolled systemic disease
- Other conditions that the subjects are not suitable to participate in this study according to the judgment of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sintilimab Combined With Regorafenib and HAIC
|
200mg IV d1,Q3W
Other Names:
hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Other Names:
80mg/day,PO,QD,d1~21,Q4W
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: up to 24 months
|
Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0
|
up to 24 months
|
Overall response rate ( ORR)
Time Frame: up to 24 months
|
Defined as proportion of patients who have a best response of CR or PR
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate (DCR)
Time Frame: up to 24 months
|
Defined as proportion of patients who have a best response of CR, PR or SD
|
up to 24 months
|
Duration of response (DoR)
Time Frame: up to 24 months
|
Defined as the time from first confirmed response (CR or PR) to the date of the first documented tumor progression or death due to any cause, whichever occurs first.
|
up to 24 months
|
Progression free survival (PFS)
Time Frame: up to 28 months
|
Defined as the time from enrollment to disease progression or death, whichever occurs first
|
up to 28 months
|
Overall survival (OS)
Time Frame: up to 28 months
|
Defined as the time from the date of treatment start to the date of death
|
up to 28 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 1, 2022
Primary Completion (ANTICIPATED)
March 1, 2024
Study Completion (ANTICIPATED)
December 1, 2024
Study Registration Dates
First Submitted
August 26, 2022
First Submitted That Met QC Criteria
August 31, 2022
First Posted (ACTUAL)
September 1, 2022
Study Record Updates
Last Update Posted (ACTUAL)
September 1, 2022
Last Update Submitted That Met QC Criteria
August 31, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SRHCL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Sintilimab
-
Beijing Tiantan HospitalRecruiting
-
RemeGen Co., Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (USA), Inc.WithdrawnMetastatic Cutaneous Melanoma | Unresectable Cutaneous MelanomaUnited States, Germany, France, Australia, Spain, Switzerland, United Kingdom
-
Zhejiang Cancer HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
The First Hospital of Jilin UniversityActive, not recruitingLocally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | TislelizumabChina
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Wuhan UniversityRecruitingEsophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityInnovent Biologics (Suzhou) Co. Ltd.UnknownPediatric CancerChina